Publications

AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model

Source

Lin K, Good SS, Julander JG, Weight AE, Moussa A, Sommadossi J-P (2022) AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model. PLoS Negl Trop Dis 16(1): e0009937.

A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase

Source

Shannon, A., Fattorini, V., Sama, B. et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat Commun 13, 621 (2022).

Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses

Source

AAC Accepted Manuscript Posted Online 23 August 2021 Antimicrob Agents Chemother doi:10.1128/AAC.00988-21

AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19

Source

Published in Antimicrobial Agents and Chemotherapy. 2021. DOI: 10.1128/AAC.02479-20

Preclinical Evaluation of AT-527, a Novel Guanosine Nucleotide Prodrug with Potent, Pan-genotypic Activity Against Hepatitis C Virus

Source

Published in PLoS ONE. 2020. DOI: e0227104.

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Source

Published in Antimicrobial Agents & Chemotherapy. 2019. Volume 63, Issue 12. DOI: 10.1128/AAC.01201-19.

First page
Previous page
Page 1
Page 2
Current page 3

Investor Relations

Publications

Publications